Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NexImmune
Biotech
NexImmune halves team as cash forces focus on core capabilities
Running close to the end of its cash runway, the immunotherapy biotech is halving its head count to support investment in its nanoparticle platform.
Nick Paul Taylor
Sep 1, 2023 6:39am
Hutchmed, NightHawk and NexImmune drop R&D programs
Nov 15, 2022 8:30am
NexImmune cites tough competition for pausing myeloma plans
Aug 16, 2022 8:35am
After bagging Yescarta exec as CMO, NexImmune files for IPO
Jan 21, 2021 7:25am
